← Russell 3000 cross-section

NOVT NOVANTA INC

Trailing twelve months to 2026-07-03 · as filed 2026-08-05, not restated
Industrials

Scale

Market cap
$5.5bn
Revenue TTM
$1.0bn
Net income TTM
$62m
Free cash flow
$114m
Composite score
36.7
Sector rank
#1024

Valuation

P / E
88.7
EV / EBITDA
32.2
EV / sales
4.8
FCF yield
2.09%
Earnings yield vs 10-yr
-3.60pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.0%
EBITDA margin
14.9%
ROE
3.8%
ROIC
8.5%
Revenue growth
7.6%

Insider activity, last 90 days

Net open-market
$-2.14m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Medical Market For the six months ended July 3, 2026, the medical market accounted for approximately 52% of our revenue. Revenue from our products sold to the medical market is generally affected by hospital, life science, and other healthcare provider capital spending, growth rates of surgical procedures, changes in regulatory requirements and laws, demand level for life science automation technology, aggregation of purchasing by healthcare networks, changes in technology requirements, timing of OEM customers’ product development and new product launches, changes in customer or patient preferences, and general demographic trends. …NOVANTA INC, 10-Q, period ended 2026-07-03, filed 2026-08-05

Read the full passage →